FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2186984829> ?p ?o ?g. }

• W2186984829 endingPage "8" @default.
• W2186984829 startingPage "4595" @default.
• W2186984829 abstract "Ligand-independent activation of the androgen receptor (AR) by cytokines has been implicated in the progression of androgen-independent prostate cancer (PCa). To determine the potential effects of elevated levels of interleukin-4 (IL-4) in patients with PCa, six different cytokines were examined for their ability to activate the AR.LNCaP cells were transiently transfected with prostate-specific antigen (PSA) (-630 / +12)-luciferase and treated with R1881, six kinds of cytokines including IL-4, or vehicle. Transactivation assays were also performed in LNCaP cells co-transfected with the 5xGal4UAS-TATA-luciferase and AR-(1-558)-Gal4DBD prior to incubation with R1881, IL-4, IL-6, or vehicle. Seventy-two patients with pre-treatment PCa, 17 patients with hormone-refractory metastatic PCa receiving androgen ablation therapy, 20 patients with benign prostatic hypertrophy and 10 healthy male volunteers were enrolled in this retrospective study. The concentration of serum IL-4 was measured by chemiluminescence enzyme immunoassay.IL-4 induced androgen-response element-driven reporters and activated the AR N-terminal domain (NTD) in a ligand-independent manner in transiently transfected LNCaP cells. Levels of IL-4 in the serum were significantly elevated in patients with hormone-refractory PCa as compared to the levels in pre-treatment PCa.IL-4 serum levels were demonstrated to be increased in honnone-refractory PCa and IL-4 was shown to enhance PSA reporter gene activity by the activation of AR NTD in human LNCaP cells. These results suggest that the AR can be activated by cytokines, and that this mechanism may play an important role in the transition from androgen-dependent to androgen-independent PCa after patients receive androgen ablation therapy." @default.
• W2186984829 created "2016-06-24" @default.
• W2186984829 creator A5006413227 @default.
• W2186984829 creator A5009396228 @default.
• W2186984829 creator A5016621337 @default.
• W2186984829 creator A5017204637 @default.
• W2186984829 creator A5022788665 @default.
• W2186984829 creator A5039530102 @default.
• W2186984829 creator A5045555834 @default.
• W2186984829 creator A5046362015 @default.
• W2186984829 creator A5056517213 @default.
• W2186984829 creator A5079207660 @default.
• W2186984829 creator A5089406877 @default.
• W2186984829 date "2005-12-13" @default.
• W2186984829 modified "2023-09-23" @default.
• W2186984829 title "Interleukin-4 in patients with prostate cancer." @default.
• W2186984829 cites W1948931726 @default.
• W2186984829 cites W1965865405 @default.
• W2186984829 cites W1969241521 @default.
• W2186984829 cites W1982552468 @default.
• W2186984829 cites W1994584656 @default.
• W2186984829 cites W2002186586 @default.
• W2186984829 cites W2008532096 @default.
• W2186984829 cites W2043236550 @default.
• W2186984829 cites W2078668858 @default.
• W2186984829 cites W2079688281 @default.
• W2186984829 cites W2103659378 @default.
• W2186984829 cites W2138120234 @default.
• W2186984829 cites W2144120552 @default.
• W2186984829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16334148" @default.
• W2186984829 hasPublicationYear "2005" @default.
• W2186984829 type Work @default.
• W2186984829 sameAs 2186984829 @default.
• W2186984829 citedByCount "11" @default.
• W2186984829 countsByYear W21869848292015 @default.
• W2186984829 countsByYear W21869848292017 @default.
• W2186984829 countsByYear W21869848292018 @default.
• W2186984829 countsByYear W21869848292021 @default.
• W2186984829 countsByYear W21869848292022 @default.
• W2186984829 crossrefType "journal-article" @default.
• W2186984829 hasAuthorship W2186984829A5006413227 @default.
• W2186984829 hasAuthorship W2186984829A5009396228 @default.
• W2186984829 hasAuthorship W2186984829A5016621337 @default.
• W2186984829 hasAuthorship W2186984829A5017204637 @default.
• W2186984829 hasAuthorship W2186984829A5022788665 @default.
• W2186984829 hasAuthorship W2186984829A5039530102 @default.
• W2186984829 hasAuthorship W2186984829A5045555834 @default.
• W2186984829 hasAuthorship W2186984829A5046362015 @default.
• W2186984829 hasAuthorship W2186984829A5056517213 @default.
• W2186984829 hasAuthorship W2186984829A5079207660 @default.
• W2186984829 hasAuthorship W2186984829A5089406877 @default.
• W2186984829 hasConcept C104317684 @default.
• W2186984829 hasConcept C121608353 @default.
• W2186984829 hasConcept C126322002 @default.
• W2186984829 hasConcept C1292079 @default.
• W2186984829 hasConcept C134018914 @default.
• W2186984829 hasConcept C150194340 @default.
• W2186984829 hasConcept C185592680 @default.
• W2186984829 hasConcept C2777911890 @default.
• W2186984829 hasConcept C2779723316 @default.
• W2186984829 hasConcept C2780192828 @default.
• W2186984829 hasConcept C2781406297 @default.
• W2186984829 hasConcept C502942594 @default.
• W2186984829 hasConcept C54009773 @default.
• W2186984829 hasConcept C54355233 @default.
• W2186984829 hasConcept C55493867 @default.
• W2186984829 hasConcept C61367390 @default.
• W2186984829 hasConcept C71315377 @default.
• W2186984829 hasConcept C71924100 @default.
• W2186984829 hasConcept C81885089 @default.
• W2186984829 hasConcept C86803240 @default.
• W2186984829 hasConceptScore W2186984829C104317684 @default.
• W2186984829 hasConceptScore W2186984829C121608353 @default.
• W2186984829 hasConceptScore W2186984829C126322002 @default.
• W2186984829 hasConceptScore W2186984829C1292079 @default.
• W2186984829 hasConceptScore W2186984829C134018914 @default.
• W2186984829 hasConceptScore W2186984829C150194340 @default.
• W2186984829 hasConceptScore W2186984829C185592680 @default.
• W2186984829 hasConceptScore W2186984829C2777911890 @default.
• W2186984829 hasConceptScore W2186984829C2779723316 @default.
• W2186984829 hasConceptScore W2186984829C2780192828 @default.
• W2186984829 hasConceptScore W2186984829C2781406297 @default.
• W2186984829 hasConceptScore W2186984829C502942594 @default.
• W2186984829 hasConceptScore W2186984829C54009773 @default.
• W2186984829 hasConceptScore W2186984829C54355233 @default.
• W2186984829 hasConceptScore W2186984829C55493867 @default.
• W2186984829 hasConceptScore W2186984829C61367390 @default.
• W2186984829 hasConceptScore W2186984829C71315377 @default.
• W2186984829 hasConceptScore W2186984829C71924100 @default.
• W2186984829 hasConceptScore W2186984829C81885089 @default.
• W2186984829 hasConceptScore W2186984829C86803240 @default.
• W2186984829 hasIssue "6C" @default.
• W2186984829 hasLocation W21869848291 @default.
• W2186984829 hasOpenAccess W2186984829 @default.
• W2186984829 hasPrimaryLocation W21869848291 @default.
• W2186984829 hasRelatedWork W1529553588 @default.
• W2186984829 hasRelatedWork W1936856060 @default.
• W2186984829 hasRelatedWork W1982552468 @default.

• next